April 29, 2013 7:34 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Protalix BioTherapeutics,Inc. (NYSE: PLX) announced today that the Mexican FederalCommission for the Protection against Sanitary Risk (COFEPRIS) and the PublicHealth Institute of Chile have both granted regulatory approval to UPLYSO™(alfataliglicerase) for the long-term enzyme replacement therapy for adultswith a confirmed diagnosis of Type I Gaucher disease. UPLYSO will be marketedin Mexico and Chile by Pfizer Inc., the Company's commercialization partner.UPLYSO is known as ELELYSO™ (taliglucerase alfa) outside of Latin America.Taliglucerase alfa was approved by the U.S. Food and Drug Administration inMay 2012 and subsequently has been approved by Israel's Ministry of Health,Brazil's ANVISA and by the regulatory authorities of other countries.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.